Physician profile
Elizabeth E Smith
NPI 1790125813
$360.95
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $84.70 · 2023: $61.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $61.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $61.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $130.41 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $119.50 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $47.77 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.98 | 2022 | |
| Merck Sharp & Dohme LLC | $20.36 | 2023 | Dificid |
| Scilex Pharmaceuticals INC. | $15.93 | 2023 | Ztlido |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.